{"id":873669,"date":"2025-08-10T08:03:10","date_gmt":"2025-08-10T12:03:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/"},"modified":"2025-08-10T08:03:10","modified_gmt":"2025-08-10T12:03:10","slug":"io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/","title":{"rendered":"IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma"},"content":{"rendered":"
\n

NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013\/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma.<\/p>\n

\n Webcast and Conference Call Information<\/strong>\n <\/p>\n

The IO Biotech management team will host a webcast\/conference call on Monday, August 11, 2025, at 8:30 a.m. ET to discuss the topline results from the Phase 3 trial of Cylembio. Those who would like to participate may access the live webcast here<\/a> or register in advance for the teleconference here<\/a> . A replay of the webcast will be available on the IO Biotech website following the live event.<\/p>\n

\n About IO Biotech<\/strong>\n <\/p>\n

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win\u00ae platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio\u00ae, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1\/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck\u2019s anti-PD-1 therapy, KEYTRUDA\u00ae (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.<\/p>\n

For further information, please visit www.iobiotech.com<\/a>. Follow us on our social media channels on LinkedIn<\/a> and X (@IOBiotech<\/a>).<\/p>\n

\n Contacts:\u00a0<\/strong>\n <\/p>\n

\n Investors\u00a0<\/strong>
\n
Maryann Cimino, Director of Investor Relations\u00a0\u00a0
IO Biotech, Inc.\u00a0
617-710-7305\u00a0
mci@iobiotech.com<\/a>\u00a0<\/p>\n

\n Media\u00a0<\/strong>
\n
Julie Funesti\u00a0
Edelman
917-498-1967
julie.funesti@edelman.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013\/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma. Webcast and Conference Call Information The IO Biotech management team will host a webcast\/conference call on Monday, August 11, 2025, at 8:30 a.m. ET to discuss the topline results from the Phase 3 trial of Cylembio. Those who would like to … <\/p>\n

Continue reading “IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-873669","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013\/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma. Webcast and Conference Call Information The IO Biotech management team will host a webcast\/conference call on Monday, August 11, 2025, at 8:30 a.m. ET to discuss the topline results from the Phase 3 trial of Cylembio. Those who would like to … Continue reading "IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-10T12:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwOTQ5MSM3MDkxMTQ0IzIyNjE0ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma\",\"datePublished\":\"2025-08-10T12:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\\\/\"},\"wordCount\":345,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwOTQ5MSM3MDkxMTQ0IzIyNjE0ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\\\/\",\"name\":\"IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwOTQ5MSM3MDkxMTQ0IzIyNjE0ODE=\",\"datePublished\":\"2025-08-10T12:03:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwOTQ5MSM3MDkxMTQ0IzIyNjE0ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwOTQ5MSM3MDkxMTQ0IzIyNjE0ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - Market Newsdesk","og_description":"NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013\/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma. Webcast and Conference Call Information The IO Biotech management team will host a webcast\/conference call on Monday, August 11, 2025, at 8:30 a.m. ET to discuss the topline results from the Phase 3 trial of Cylembio. Those who would like to … Continue reading \"IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-10T12:03:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwOTQ5MSM3MDkxMTQ0IzIyNjE0ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma","datePublished":"2025-08-10T12:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/"},"wordCount":345,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwOTQ5MSM3MDkxMTQ0IzIyNjE0ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/","name":"IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwOTQ5MSM3MDkxMTQ0IzIyNjE0ODE=","datePublished":"2025-08-10T12:03:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwOTQ5MSM3MDkxMTQ0IzIyNjE0ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwOTQ5MSM3MDkxMTQ0IzIyNjE0ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-cylembio-in-combination-with-keytruda-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/873669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=873669"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/873669\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=873669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=873669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=873669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}